Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 113 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Choosing a Gliptin

Gupta Vishal, Kalra Sanjay

Year : 2011| Volume: 15| Issue : 4 | Page no: 298-308

   This article has been cited by
1 The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy
Liberata Sportiello,Concetta Rafaniello,Cristina Scavone,Cristiana Vitale,Francesco Rossi,Annalisa Capuano
International Journal of Cardiology. 2016; 202: 731
[Pubmed]  [Google Scholar] [DOI]
2 Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis
Christian Leporini,Rosanna Piro,Francesco Ursini,Francesca Maida,Caterina Palleria,Franco Arturi,Maria Pavia,Giovambattista De Sarro,Emilio Russo
Expert Opinion on Drug Safety. 2016; 15(sup2): 17
[Pubmed]  [Google Scholar] [DOI]
3 Comparison of charges and resource use associated with saxagliptin and sitagliptin
Varun Vaidya,Keyuri Adhikari,Jack Sheehan,Iftekhar Kalsekar
Health Economics Review. 2015; 6(1)
[Pubmed]  [Google Scholar] [DOI]
4 DPP-4 inhibitors: pharmacological differences and their clinical implications
Antonio Ceriello,Liberata Sportiello,Concetta Rafaniello,Francesco Rossi
Expert Opinion on Drug Safety. 2014; 13(S1): 57
[Pubmed]  [Google Scholar] [DOI]
5 Alogliptin for the treatment of Type 2 diabetes
Yutaka Seino,Daisuke Yabe
Expert Review of Endocrinology & Metabolism. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
6 Development of a gas chromatography–mass spectrometry method for the analysis of sitagliptin in human urine
Ebru Uçaktürk
Journal of Pharmaceutical and Biomedical Analysis. 2013; 74: 71
[Pubmed]  [Google Scholar] [DOI]


Read this article